Stockscreener 앱 받기
15.88
0.37%
0.0399
전일 마감가:
$15.84
열려 있는:
$16.01
하루 거래량:
16.81M
Relative Volume:
0.81
시가총액:
$3.62B
수익:
$1.78B
순이익/손실:
$164.40M
주가수익비율:
23.01
EPS:
0.69
순현금흐름:
$236.51M
1주 성능:
+0.62%
1개월 성능:
-49.34%
6개월 성능:
-62.31%
1년 성능:
-76.87%
1일 변동 폭
$15.46
$16.55
1주일 범위
$15.46
$16.92
52주 변동 폭
$15.46
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
15.88 | 3.61B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 58.57B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.80 | 54.51B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.14 | 49.96B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.16 | 39.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
477.90 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 개시 | Evercore ISI | In-line |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-21 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-04 | 재확인 | Needham | Buy |
| 2025-04-29 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Hims & Hers Looks to Expand Globally With Buy of Australian Telehealth Provider - Barron's
Hims & Hers Health (HIMS) Rises on Eucalyptus Acquisition - GuruFocus
Hims plans to acquire Eucalyptus for up to $1.15B - Axios
Hims & Hers (HIMS) Stock: Company Acquires Eucalyptus for Up to $1.15 Billion - Blockonomi
What Is HIMS Worth Without GLP-1? Earnings Preview (NYSE:HIMS) - Seeking Alpha
4 stocks to watch on Thursday: HIMS, DPZ, WMT, PSX - Seeking Alpha
Why Is Hims & Hers Health Stock Trading Higher Today?Hims & Hers Health (NYSE:HIMS) - Benzinga
Hims & Hers under fire over copycat weight loss drugs - AOL.com
Hims & Hers to acquire Eucalyptus for up to $1.15 billion - Investing.com
Hims & Hers Health (HIMS) to Acquire Eucalyptus in $1.15 Billion Deal - GuruFocus
Hims & Hers is spending more than $1 billion in a push to expand globally - MarketWatch
US Premarket Movers: Carvana, Deere, Hims & Hers, Walmart - Bloomberg.com
Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion - WKZO
Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider - Barron's
Hims & Hers Jumps Premarket After $1.15B Global Expansion Deal - Tokenist
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal - The Wall Street Journal
Hims & Hers stock rises after agreement to acquire Eucalyptus - Investing.com UK
Hims & Hers to buy Australian digital health firm Eucalyptus for over $1B - Seeking Alpha
HIMS Acquires Eucalyptus in Deal Worth Up to $1.15 Billion - GuruFocus
Hims & Hers (HIMS) Plans Major Expansion with Eucalyptus Acquisi - GuruFocus
Hims & Hers to Acquire Eucalyptus in Global Expansion - TipRanks
Hims & Hers Health Makes Australia, Japan Foray With $1.15 Billion Eucalyptus Acquisition - Stocktwits
Hims & Hers to Acquire Eucalyptus in Deal Valued Up to $1.15 Billion - TradingView
Hims & Hers Health to acquire Australia's Eucalyptus for up to $1.15 billion - Reuters
Hims & Hers Health to Acquire Australia's Eucalyptus for up to $1.15 Billion - U.S. News & World Report
Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders - Reuters
Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform - Hims Investor Relations
How We’re Becoming the Leading Global Consumer Health Platform - Hims & Hers Newsroom
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance Singapore
Is Hims & Hers Health Inc Gaining or Losing Market Support? - Benzinga
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Hims And Hers Weighs Legal Risks Against Growth In Longevity Pivot - Yahoo Finance
Hims stock hits 52-week low at 15.62 USD - Investing.com India
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings (NYSE:HIMS) - Seeking Alpha
Do You Think Hims & Hers Health (HIMS) is Positioned for Long-Term Growth? - Insider Monkey
Pre-Market: HIMS (Hims & Hers NYSE) $16.27 on 18 Feb 2026: earnings in focus - Meyka
Deutsche Bank Cite Near-Term Growth Concerns For Hims & Hers Health, Inc. (HIMS) Following GLP-1 Launch Reversal - Finviz
How Ozempic Brought a Napster Moment to Big Pharma - The Wall Street Journal
Market Whales and Their Recent Bets on HIMS Options - Benzinga
Novo Nordisk Patent Fight With Hims And Hers Puts Valuation In Focus - Yahoo Finance
Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month’s 48% Selloff - 24/7 Wall St.
Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for - Finviz
Hims & Hers Health Stock (HIMS) Opinions on Earnings Beat - Quiver Quantitative
Short Sellers Target Hims & Hers Amid Regulatory and Legal Challenges - AD HOC NEWS
Hims & Hers Health (HIMS) to Release Earnings on Monday - MarketBeat
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’ - AOL.com
Hims & Hers is a brave bet on solving disrupter’s dilemma - Financial Times
Hims & Hers (HIMS) soars 16% on bullish analyst outlook - MSN
Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of "Hold" by Brokerages - MarketBeat
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows - WHTC
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
1.13%
자본화:
|
볼륨(24시간):